TFDA approval for CAL056 mesylate was gained on February 9th, 2021 to conduct multi-center Phase I clinical trial in US and Taiwan. The trial will be conducted at Taipei Tzu Chi Hospital in Taiwan.
©2024 Calgent Biotechnology Co. Ltd. All rights reserved. 網頁設計公司：振作國際